<DOC>
	<DOCNO>NCT01736007</DOCNO>
	<brief_summary>Alopecia Areata ( AA ) skin restrict autoimmune disease hair follicle , result hair loss scalp , severe case entire body . AA second common cause alopecia childhood ; FDA-approved treatment exist . The use focus narrow-band ultraviolet-B light via excimer laser common treatment many skin disease patient age . In study , feasibility 308-nm excimer laser treatment patch type AA scalp examine . We anticipate excimer laser safe feasible option patient patch type AA . The excimer laser may represent novel treatment childhood AA comparison large study currently exist literature . Hypotheses The 308-nm excimer laser procedure feasible , well-tolerated safe treatment patch type alopecia areata scalp child .</brief_summary>
	<brief_title>Childhood Alopecia Areata Study Using 308-nm Excimer Laser</brief_title>
	<detailed_description>The goal study assess feasibility , safety response treatment use 308-nm excimer laser child ( age 6-17 year ) diagnose patch type alopecia areata involve scalp , present 6 month duration . Patients meet inclusion criterion randomly enrol treatment group placebo group . Response treatment 12-week laser treatment course measure term hair regrowth utilize SALT score 2 blinded evaluation subject photograph . Specific Aims Evaluate feasibility safety twice-weekly excimer laser treatment period 12 week . Measures include side effect , response treatment ( hair growth ) , tolerability therapy , attrition , attendance , overall satisfaction treatment modality .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>1 . Children 617 year old , diagnosed patch type alopecia areata minimum 6 month prior enrollment involve scalp . 2 . A Parent/guardian consent child assent ( 8 year old great ) must obtain . 3 . Parent/guardian patient agree MED dose test 24 hour follow visit 12 week period twice weekly treatment either group , well baseline , interim end study visit . 4 . Parent/guardian child must able understand English Spanish participate . 5 . Parent/guardian must agree patient undergo washout period 6 week prior enrollment study patient currently treatment kind ( oral and/or topical ) AA . 1 . Children diagnose autoimmune skin disease photosensitivity disorder . 2 . Children use topical steroid scalp , scalp disease use injected oral steroid , biologic agent chemotherapy medical condition . 3 . Children current treatment skin condition oral medication ( oral corticosteroid ) and/or topical treatment topical corticosteroid may affect hair regrowth . Specifically , topical medication , child require use class 12 topical corticosteroid exclude . 3 . Any subject currently experience significant spontaneous regrowth terminal hair . 4 . Patients alopecia universalis , totalis , ophiasis pattern diffuse AA may participate feasibility study . 4 . Parent/guardian consent child assent participate . 5 . Any subject AA le 6 month willing undergo 6 week washout period prior start study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>alopecia areata child</keyword>
	<keyword>scalp</keyword>
</DOC>